Ensysce Biosciences (NASDAQ:ENSC – Get Rating) is one of 944 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Ensysce Biosciences to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.
Risk and Volatility
Ensysce Biosciences has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Ensysce Biosciences’ peers have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
26.9% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 45.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 52.7% of Ensysce Biosciences shares are held by insiders. Comparatively, 15.1% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Ensysce Biosciences and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ensysce Biosciences Competitors||2628||12322||38458||607||2.69|
Ensysce Biosciences presently has a consensus price target of $4.00, indicating a potential upside of 776.81%. As a group, “Pharmaceutical preparations” companies have a potential upside of 117.62%. Given Ensysce Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Ensysce Biosciences is more favorable than its peers.
This table compares Ensysce Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ensysce Biosciences Competitors||-3,128.59%||-1,451.29%||-9.09%|
Valuation and Earnings
This table compares Ensysce Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ensysce Biosciences||$3.53 million||-$29.08 million||-0.36|
|Ensysce Biosciences Competitors||$1.85 billion||$250.15 million||-2.67|
Ensysce Biosciences’ peers have higher revenue and earnings than Ensysce Biosciences. Ensysce Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Ensysce Biosciences peers beat Ensysce Biosciences on 7 of the 13 factors compared.
About Ensysce Biosciences (Get Rating)
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.